Anti-Vβ17 / anti-CD123 bispecific antibodies

Optimized anti-Vβ17/anti-CD123 bispecific antibodies address low activity issues by improving cytotoxicity, achieving up to 77% target cell killing at optimal ratios and concentrations.

AU2020235475B2Pending Publication Date: 2026-07-16JANSSEN BIOTECH INC
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
JANSSEN BIOTECH INC
Filing Date
2020-03-11
Publication Date
2026-07-16

AI Technical Summary

Technical Problem

Existing bispecific antibodies targeting Vβ17 and CD123 exhibit low activity and undetectable cytotoxicity against target cells, limiting their effectiveness in therapeutic applications.

Method used

Development of anti-Vβ17/anti-CD123 bispecific antibodies with optimized epitope targeting and enhanced cytotoxicity through specific antibody ratios and concentrations.

Benefits of technology

The optimized bispecific antibodies demonstrate significant cytotoxicity against target cells, achieving up to 77% cytotoxicity at optimal ratios and concentrations, enhancing their therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000001_0000
    Figure 00000001_0000
  • Figure 00000061_0000
    Figure 00000061_0000
  • Figure 00000062_0000
    Figure 00000062_0000
Patent Text Reader

Abstract

The present disclosure relates to Vβ17 / CD123 bispecific antibodies. The antibodies are characterized by their CDRs sequences. Toxicity experiments are performed on Kasumi-3 cells (used to perform acute myeloblastic leukaemia pathologies)
Need to check novelty before this filing date? Find Prior Art